PUM1 Is Overexpressed in Colon Cancer Cells With Acquired Resistance to Cetuximab

BACKGROUND: Cetuximab is an effective antibody to treat colorectal cancer (CRC) by targeting the epidermal growth factor receptor (EGFR). However, the mechanisms of acquired resistance to cetuximab therapy, especially in patients without identifiable gene mutations, are not fully understood. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qizhi, Xin, Cheng, Chen, Yikuan, Yang, Jiawen, Chen, Yingying, Zhang, Wei, Ye, Lechi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383298/
https://www.ncbi.nlm.nih.gov/pubmed/34447749
http://dx.doi.org/10.3389/fcell.2021.696558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383298/
https://www.ncbi.nlm.nih.gov/pubmed/34447749
http://dx.doi.org/10.3389/fcell.2021.696558

Ejemplares similares